Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1656553 | 0.89 | DNM1 (0.40) | DNM1EPHX1CA1CA2ALDH1A1 | |
| SCHEMBL8639866 | 0.83 | DNM1 (0.50) | DNM1EPHX1CA1CA2ALDH1A1 | |
| SCHEMBL4141679 | 0.82 | DNM1 (0.53) | DNM1EPHX1ALDH1A1 | |
| SCHEMBL28945728 | 0.82 | DNM1 (0.53) | DNM1EPHX1ALDH1A1 | |
| SCHEMBL28389824 | 0.82 | DNM1 (0.53) | DNM1EPHX1ALDH1A1 | |
| SCHEMBL7673548 | 0.81 | CA1 (0.43) | DNM1EPHX1CA1CA2ALDH1A1 | |
| SCHEMBL8672648 | 0.79 | CDC25A (0.32) | DNM1ALDH1A1 | |
| SCHEMBL5203783 | 0.78 | GAA (0.33) | DNM1EPHX1CA1CA2ALDH1A1 | |
| SCHEMBL25429944 | 0.76 | — | — | |
| SCHEMBL6579073 | 0.76 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678185-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005042542-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-05-12 | — | — | WO | disclosed |